Abstracts tagged "Pharmacoepidemiology"

Abstract Number: 2519 • ACR Convergence 2025
A Disproportionality Analysis of FDA Adverse Event Reporting System (FAERS) Events for Avacopan
Shiamak Cooper¹, Asim Khanfar², Yousef al-mabrouk³, Omar Hamdan⁴ and Anthony Ocon⁵, ¹Rochester General Hospital, Irondequoit, NY, ²Rochester General Hospital, Rochester, NY, ³Prince Hanza Hospital, Amman, Jordan, ⁴University of Jordan, Az-Zarqa, Jordan, ⁵Rochester Regional Health, Fairport, NY
Background/Purpose: Avacopan, a C5a receptor inhibitor, is used as an adjunctive treatment for ANCA-associated vasculitis. Previous studies have highlighted its efficacy in reducing glucocorticoid use…
Abstract Number: 1042 • ACR Convergence 2025
Biosimilar adalimumab prescriptions increase before the CVS formulary change and decrease after
Eric Roberts¹, gabriela Schmajuk², Diana Ung³, Mackenzie Clark³ and Jinoos Yazdany⁴, ¹University of California, San Francisco, SF, CA, ²University of California, San Francisco, and San Francisco Veterans Affairs Medical Center, San Francisco, CA, ³UCSF, San Francisco, ⁴UCSF, San Francisco, CA
Background/Purpose: In 2023 patent exclusivity for adalimumab expired and nine biosimilars were introduced to the U.S. market with a tenth launched in May 2024. The…
Abstract Number: 2343 • ACR Convergence 2025
Risk of Arrhythmias Following IL-17 Inhibitor Use; A Pharmacosurvellience Study of FDA Adverse Event Reporting System (FAERS)
Asim Khanfar¹, Omar Hamdan², Anil Regmi³, Mayra Goreja⁴ and Anthony Ocon⁵, ¹Rochester General Hospital, Rochester, NY, ²University of Jordan, Az-Zarqa, Jordan, ³Parkview Health, Fort Wayne, IN, ⁴Rochester General Hospital, Rochester, ⁵Rochester Regional Health, Fairport, NY
Background/Purpose: Interleukin-17 (IL-17) inhibitors, such as secukinumab and ixekizumab, are used for their anti-inflammatory effects in conditions like psoriasis and ankylosing spondylitis. IL-17 signaling has…
Abstract Number: 0666 • ACR Convergence 2025
Reported Adverse Events Associated With Systemic Lupus Erythematosus (SLE) Treatment: Insights From the FDA Adverse Event Reporting System (FAERS) 2023
Sarah Crisci, New York University, New York, NY
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease with heterogeneous symptoms, complicating diagnosis and treatment. Historically, treatment included broad immunosuppressants, but real-world data…
Abstract Number: 2287 • ACR Convergence 2025
Interpretable Ensemble Machine Learning Explaining Nonadherence and the Risk of Nonpersistence of Targeted Disease-Modifying Antirheumatic Agents in Older Adults with Rheumatoid Arthritis
yinan huang¹ and Sandeep Agarwal², ¹Department of Pharmacy Administration, University of Mississippi, Oxford, MS, US, MS, ²Baylor College of Medicine, Houston
Background/Purpose: Interpretable machine learning (ML) method can identify factors associated with biological or targeted synthetic disease modifying antirheumatic drugs (b/tsDMARDs) nonadherence and nonpersistence for rheumatoid…
Abstract Number: 0818 • ACR Convergence 2025
Risk of Cardiovascular Events is Higher in Pregabalin Users Versus Duloxetine: A Cohort Study Among Veterans with Chronic Musculoskeletal Pain
Sachalee Campbell¹, Laura Daniel², Puran Nepa², Otis Wilson³, Alyson L. Dickson³, Katherine Murray³, William D. Dupont³, Adriana Hung³, Wayne A. Ray³, Michael Stein⁴ and Cecilia P. Chung², ¹University of Miami, Miami, FL, ²University of Miami, Research Service, Miami VA Healthcare System, Miami, FL, ³Vanderbilt University Medical Center, Vanderbilt, TN, ⁴Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Pregabalin and duloxetine are among the most prescribed non-opioid medications for patients with chronic pain. Pregabalin may raise the risk for heart failure, and…
Abstract Number: 2214 • ACR Convergence 2025
Hydroxychloroquine and Pregnancy Outcomes in Lupus: Results from a population-based cohort study
Sadaf Sediqi¹, leo lu², J. Antonio Aviña-Zubieta³ and Julia F Simard⁴, ¹Stanford University, Palo Alto, CA, ²Arthritis Research Canada, Vancouver, BC, Canada, ³University of British Columbia/Arthritis Research Canada, Vancouver, BC, Canada, ⁴Stanford Medicine, Stanford, CA
Background/Purpose: Systemic lupus erythematosus (SLE) can pose an increased risk of adverse pregnancy outcomes such as preeclampsia and preterm delivery. Hydroxychloroquine (HCQ), commonly used to…
Abstract Number: 0479 • ACR Convergence 2025
Risk of Arrhythmias Following IL-6 Inhibitor Use; A Pharmacosurvellience Study of FDA Adverse Event Reporting System (FAERS)
Asim Khanfar¹, Omar Hamdan², Shiamak Cooper³, Sanjana Thimmannagari¹ and Anthony Ocon⁴, ¹Rochester General Hospital, Rochester, NY, ²University of Jordan, Az-Zarqa, Jordan, ³Rochester General Hospital, Irondequoit, NY, ⁴Rochester Regional Health, Fairport, NY
Background/Purpose: Interleukin-6 (IL-6) inhibitors, including tocilizumab and sarilumab, are immunomodulatory agents commonly used in the treatment of rheumatoid arthritis and COVID-19. Prior studies have implicated…
Abstract Number: 2087 • ACR Convergence 2025
Does Carbamazepine Impact Risk of Developing Osteoarthritis? Results of a Real-World Data Analysis
Erfan Afshar¹ and Andrew Long², ¹VCUSOM, Richmond, VA, ²Virginia Commonwealth University Health System, Midlothian, VA
Background/Purpose: Carbamazepine has shown chondroprotective effects in OA animal models by modulating Nav1.7 channels. This study aimed to examine the association between Carbamazepine use and…
Abstract Number: 0478 • ACR Convergence 2025
Racial and Ethnic Disparities in DMARD Use and in Medicare Part B-Covered Options Among Medicare Beneficiaries with Late-Onset Rheumatoid Arthritis
ashkan ara¹, John FitzGerald² and Susan Ettner², ¹UCLA Health, Los Angeles, CA, ²UCLA, Los Angeles, CA
Background/Purpose: Biologic and targeted synthetic DMARDs can substantially improve the quality of life for Medicare beneficiaries with rheumatoid arthritis (RA). However, racial and ethnic disparities…
Abstract Number: 2008 • ACR Convergence 2025
Exposure to Anaerobic Antibiotics and Risk of Gout Flares: Target Trial Emulation for the Potential Role of the Gut Microbiome in Gout and Chronic Kidney Disease (CKD)
Natalie McCormick¹, Sharan Rai², Chio Yokose³, leo lu⁴, Robert Terkeltaub⁵, Lama Nazzal⁶, Huilin Li⁶, Dylan Dodd⁷ and Hyon K. Choi⁸, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital/Harvard Medical School, Boston, MA, ³Massachusetts General Hospital, Waltham, MA, ⁴Arthritis Research Canada, Vancouver, BC, Canada, ⁵Retired, San Diego, CA, ⁶NYU Langone, New York, NY, ⁷Stanford University, Palo Alto, CA, ⁸MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA
Background/Purpose: As reported in Cell Press journals,1,2 intestinal commensal purine-degrading bacteria anaerobically degrade urate to anti-inflammatory short chain fatty acids, including butyrate, and thus may…
Abstract Number: 0267 • ACR Convergence 2025
Pharmacosurvellience study of FDA Adverse Event Reporting System (FAERS) events of Secukinumab and Guselkumab
NUR BARLAS¹, Sait Barlas¹ and Emre Adalier², ¹Florida State University College of Medicine, Cape Coral, ²University of Pavia School of Medicine & Surgery, Pavia, Italy
Background/Purpose: Interleukin-17 (IL-17) and interleukin-23 (IL-23) inhibitors have revolutionized treatment for psoriatic arthritis, axial spondyloarthritis, and moderate-to-severe plaque psoriasis. IL-17 inhibitors block the pro-inflammatory cytokine…
Abstract Number: 2003 • ACR Convergence 2025
Evaluating Patient Outcomes Pre and Post Pegloticase Initiation among Uncontrolled Gout Patients: Findings from MORE2 Registry and Medicare Fee-For-Service Claims Data
Julia Buchfuhrer¹, Niranjan Kathe², Elizabeth Ibiloye³, Seth Kuranz⁴, Virginia Noxon-Wood⁴, Alexis Woods⁵ and Laurence Gozalo⁴, ¹JB Arthritis and Rheumatology Center, Downey, CA, ²Amgen Inc, San Diego, CA, ³Amgen Inc, Thousand Oaks, CA, ⁴Inovalon, Bowie, MD, ⁵Amgen, Detroit, MI
Background/Purpose: Among patients (pts) with chronic refractory gout (CRG), traditional urate lowering therapies are often inadequate, necessitating advanced therapies. Pegloticase, a recombinant uricase enzyme, rapidly…
Abstract Number: 0247 • ACR Convergence 2025
Use of Nintedanib in Patients with Progressive Pulmonary Fibrosis
Elizabeth Volkmann¹, Steven Nathan², Karen Coeytaux³, Yanni Fan⁴, Jill Curran³, Haikun Bao³, Kamila Sroka-Saidi⁵, Ann Chauffe⁶ and Jeffrey J Swigris⁷, ¹Division of Rheumatology, Department of Medicine, University of California, David Geffen School of Medicine, Los Angeles, CA, USA, Los Angeles, CA, ²Inova Advanced Lung Disease and Transplant Program, Falls Church, VA, USA, Falls Church, ³Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA, Ridgefield, ⁴Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA, Ridgefield, CT, ⁵Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, ⁶Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA, Newberry, FL, ⁷Center for Interstitial Lung Disease, Division of Pulmonary, Critical Care and Sleep Medicine, National Jewish Health, Denver, CO, USA, Denver
Background/Purpose: Nintedanib was approved in the US for the treatment of chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype (progressive pulmonary fibrosis [PPF])…
Abstract Number: 1926 • ACR Convergence 2025
Real World Rate of Efficacy of Adalimumab Biosimilars Following a Mandated Switch in an Academic Medical Center
Katharine McCarthy, viktoriya avlasevich and Darren Tabechian, URMC, Rochester, NY
Background/Purpose: The proliferation of similar biotherapeutic products (biosimilars) has helped to reduce the cost burden of biologic therapies for health care systems1. Multiple studies have…

1
2
3
…
9
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].